The raw data of Development of paclitaxel-loaded poly(lactic acid)/hydroxyapatite core–shell nanoparticles as a stimuli-responsive drug delivery system

Biodegradable nanoparticles have been well studied as biocompatible delivery systems. Nanoparticles of less than 200 nm in size can facilitate the passive targeting of drugs to tumour tissues and their accumulation therein via the enhanced permeability and retention (EPR) effect. Recent studies have focused on stimuli-responsive drug delivery systems (DDS) for improving the effectiveness of chemotherapy; for example, pH-sensitive DDS depend on the weakly acidic and neutral extracellular pH of tumour and normal tissues, respectively. In our previous work, core–shell nanoparticles composed of the biodegradable polymer poly(lactic acid) (PLA) and the widely used inorganic biomaterial hydroxyapatite (HAp, which exhibits pH sensitivity) were prepared using a surfactant-free method. These PLA/HAp core–shell nanoparticles could load 750 wt% of a hydrophobic model drug. In this work, the properties of the PLA/HAp core–shell nanoparticles loaded with the anti-cancer drug paclitaxel (PTX) were thoroughly investigated <i>in vitro</i>. Because the PTX-containing nanoparticles were approximately 80 nm in size, they can be expected to facilitate efficient drug delivery via the EPR effect. The core–shell nanoparticles were cytotoxic towards cancer cells (4T1). This was due to the pH sensitivity of the HAp shell, which is stable in neutral conditions and dissolves in acidic conditions. The cytotoxic activity of the PTX-loaded nanoparticles was sustained for up to 48 h, which was suitable for tumour growth inhibition. These results suggest that the core–shell nanoparticles can be suitable drug carriers for various water-insoluble drugs.